1. Home
  2. JAGX vs SCNI Comparison

JAGX vs SCNI Comparison

Compare JAGX & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$2.73

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

SCNI

Scinai Immunotherapeutics Ltd.

HOLD

Current Price

$0.40

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JAGX
SCNI
Founded
2013
2003
Country
United States
Israel
Employees
47
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.2M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
JAGX
SCNI
Price
$2.73
$0.40
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$60.00
N/A
AVG Volume (30 Days)
71.5K
197.2K
Earning Date
04-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
82.42
50.00
EPS
N/A
N/A
Revenue
$11,511,000.00
N/A
Revenue This Year
$61.58
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.41
52 Week High
$8.00
$3.47

Technical Indicators

Market Signals
Indicator
JAGX
SCNI
Relative Strength Index (RSI) 47.96 35.83
Support Level $1.74 N/A
Resistance Level $4.13 $0.94
Average True Range (ATR) 0.39 0.05
MACD -0.16 -0.00
Stochastic Oscillator 2.11 11.02

Price Performance

Historical Comparison
JAGX
SCNI

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

About SCNI Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.

Share on Social Networks: